Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated

Emergency Medicine Journal

Volumn 24, Issue 2, 2007, Pages 96-99

  Kobayashi, Adam ^a,b   Skowronska, Marta ^a   Litwin, Tomasz ^b   Czlonkowska, Anna ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; GLUCOSE;

AGE DISTRIBUTION; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FACTUAL DATABASE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; SYMPTOMATOLOGY; THROMBOCYTE COUNT; TIME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CRITICAL PATHWAYS; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; INFUSIONS, INTRAVENOUS; NEUROLOGY; REGISTRIES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33846848006     PISSN: 14720205     EISSN: None     Source Type: Journal    
DOI: 10.1136/emj.2006.040204     Document Type: Article

References (24)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Katzan IL, Furlan AJ, Lloyd LE, et al Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA 2000;283:1151-8.
3. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-20.
4. SITS Monitoring Study (SITS-MOST). Final study protocol. 2002; 1-65 (137 screens). http://www.acutestroke.org/SM_Protocol/ SITS-MOST_final_protocol.pdf (accessed 15 Dec 2006).
5. Pancioni AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998;279:1288-92.
6. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
7. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
8. Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006;36:483-8.
9. Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank: design, methods and baseline characteristics. Stroke 1998;19:547-54.
10. Hill MD, Barber PA, Demchuck AM, et al. Building a brain attack team for thrombolytic therapy in acute ischemic stroke. Can Med Assoc J 2000;162:1589-93.
11. Kleindorfer D, Kissela B, Schneider A, for the Neuroscience Institute, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke. A population-based study. Stroke 2004;35:e27-9.
12. Jorgensen HS, Nakayama H, Kammersgaard LP, et al. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. BMJ 1999;319:288-9.
13. Schneider AT, Pancioli AM, Khoury JC, et al. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA 2003;289:343-6.
14. Schroeder EB, Rosamond WD, Morris DL, et al. Determinants of use of emergency medical services in a population with stroke symptoms: the Second Delay in Accessing Stroke Healthcare (DASH II) Study. Stroke 2000;31:2591-6.
15. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000;31:370-5.
16. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-8.
17. Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795-8.
18. Berrouschot J, Rother J, Glahn J, et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80) stroke patients. Stroke 2005;36:2421-5.
19. Mouradian MS, Senthilselvan A, Jickling G, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry 2005;76:1234-7.
20. Van Oostenbrugge RJ, Hupperts RMM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry 2006;77:375-7.
21. Lyden P, Lu M, Kwiatkowski T, et al. Thrombolysis in patients with transient neurologic deficits. Neurology 2001;57:2125-8.
22. Caplan LR. Treatment of acute stroke. Still struggling. JAMA 2004;292:1883-5.
23. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7.
24. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36:2500-3.